VRTXVertex Pharmaceuticals
Price
+28%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, nothing alarming, price roughly fair, growing in the filings, the market undecided.
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. We have approved medicines for cystic fibrosis (“CF”), sickle cell disease (“SCD”), transfusion dependent beta thalassemia (“TDT”), and acute pain, and we continue to serially innovate and advance next-generation clinical and research programs in these areas.
In the company’s own words · 10-K filed Feb 13, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Vertex Pharmaceuticals (VRTX) reported revenue of $3.33B in Q2 2026 (quarter ended Jun 30, 2026), up 12% from the same quarter a year earlier. That came with a gross margin of 85% and net income of $1.10B (33% of revenue). For the full year FY2025, revenue was $12.0B (+8.9% year on year) and net income $3.95B. Its largest product in Q2 2026 was TRIKAFTAKAFTRIO at $2.50B, 75% of the disclosed total, well ahead of ALYFTREK at 17%. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 20, 2026On October 20, 2026, Daniel Brennan was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”)Director or officer change · Form 8-K
- Sep 1, 2026On August 27, 2026, Vertex Pharmaceuticals Incorporated (the “Company”) appointed Jonathan Poole as Executive Vice President and Chief Financial Officer of the Company, effective January 1, 2027 (the “Effective Date”)Director or officer change · Form 8-K
- Aug 3, 2026Vertex Reports Second Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $3.33BThe company’s own SEC segment disclosure.
- TRIKAFTAKAFTRIO$2.50B75%
- ALYFTREK$573.6M17%
- Manufactured Product Other$137.1M4%
- CASGEVY$76.4M2%
- JOURNAVX$49.6M1%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Biotechnology
The closest names by size in the same industry